The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
Sydney's superstar chef Neil Perry, behind Gran Torino, Margaret, and Qantas menus, isn't fazed by the Ozempic craze. He pledges to continue creating beautiful food for those who love to eat. In a bold GLP-1 warning, Perry hints at potential lawsuits ahead.
Trey Luker-Stewart lost 60 pounds on Ozempic, but it transformed his drinking from fun nights to anxious, emotional ones with brutal hangovers. As a Dallas bar owner, he's seen a 35% drop in alcohol sales linked to GLP-1 drugs. Doctors reveal why these medications blunt alcohol's rewards and worsen next-day effects.
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
South African DJ Shimza set the record straight on Podcast and Chill, firmly denying rumors that his impressive weight loss came from Ozempic or that he profits from government tenders. With his partner Athi Geleba in a high-profile Presidency position, speculation ran wild—but Shimza insists he earns his money through hard work. This candid interview sheds light on celebrity health rumors and tender controversies.
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
Kelly Osbourne's black sequined mini dress at the BRIT Awards turned heads for more than fashion—her slimmer frame ignited Ozempic speculation. Joined by Demi Moore, Emma Stone, and others at 2026 red carpets, these stars' dramatic weight loss sparked debates on 'Ozempic face' and Hollywood beauty standards. Discover the details and medical context.
Obesity rates hit 40% in 2022, but GLP-1 drugs are turning the tide with 15-20% weight loss. USC Schaeffer Center research shows broad access could add nearly two years of life for young adults and save Medicare $175-245 billion. Yet, limited insurance coverage blocks millions from these life-changing treatments.
